Open Mobile Menu

Mr. Renaud joined Bain Capital Life Sciences in 2022. From 2014 to 2021, he was Chief Executive Officer of Translate Bio (Nasdaq: TBIO) which was acquired by Sanofi in 2021. Prior to that he was President and Chief Executive Officer of Idenix Pharmaceuticals (Nasdaq: IDIX) which was acquired by Merck in 2014. Prior to his career in the biotech industry, Ron was a biotechnology research analyst at JP Morgan and Bear Stearns. Earlier in his career, Ron held various roles at Amgen (Nasdaq: AMGN) as well as at the Dana-Farber Cancer Institute.

Mr. Renaud received an MBA from the University of Southern California Marshall School of Business and a BA from Saint Anselm College.

Mr. Field joined Bain Capital Life Sciences in 2020 as an Associate. Prior to joining Bain Capital, Mr. Field was a management consultant at Bain & Company in New York. At Bain & Co, Mr. Field advised healthcare and private equity clients across a range of different strategic and operational problems. Mr. Field also worked in Commercial Strategy and Investor Relations at a biotech company prior to joining Bain Capital.

Mr. Field graduated magna cum laude from Dartmouth College, where he earned a B.A. in Biology and Economics.